FDA marketing police most likely to slap pharma for risk-info omissions

Want a surefire path to an Office of Prescription Drug Promotion (OPDP) warning letter? Leave side effects out of a drug promo, a new analysis says. As a team of Johnson & Johnson ($JNJ) execs found, 60% of the FDA warning letters and untitled letters issued by OPDP between 2013 and 2015 cited pharma for omitting risk information in promotional materials. More from FiercePharmaMarketing